More S'poreans Going Abroad for IVF to Choose Baby's Gender
By Asia One,
Asia One
| 08. 22. 2011
More and more Singaporeans are heading overseas for medical procedures which allow them to choose their babies' gender.
According to The Straits Times, foreign destinations such as the United States, and increasingly Thailand, let parents choose the gender of their babies through a procedure known as preimplantation genetic diagnosis (PGD), which is banned in Singapore.
These places are also well-known for their skills in in-vitro fertilisation (IVF).
Having sons important for people of Chinese ancestry
The managing director of Marvel IVF Solutions, an IVF facility in Bangkok, said 90 per cent of Singaporeans, Chinese nationals and Hong Kongers ask for boys.
That is because males are seen as heirs and capable of taking care of their siblings, the director said.
Other facilities such as Safe Fertility and PGD Centre in Bangkok and Fertility Institutes in Los Angeles also saw the same requests by Singaporean patrons, according to The Straits Times.
Embryos screened for gender or genetic diseases or both
PGD is carried out with IVF treatment and the embryos are screened for gender or genetic diseases or both, during the...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...